Conventional systematic core biopsies might fail to detect clinical significant prostate cancer. ARTEMIS MRI-ultrasound fusion guided prostate biopsy (ART-PBx) might overcome this issue by improving the targeting of suspicious lesions. In a retrospective clinical study including 194 patients (243 lesions) we determined a target performance of 56.3 % positive biopsies related to histopathology. The detection rate rises up to 71.4% for high score lesions (PIRADS 5) but did not show any correlation with lesion’s size. This target methodology based on MRI achieves greater detection rate of clinical significant prostate cancer, improving the ability to appropriately counsel patients regarding therapy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords